Medtronic Announces Groundbreaking Results from ADAPT-PD Trial, Showcasing Effectiveness of BrainSense™ Adaptive DBS for Parkinson's Patients
Medtronic plc has published results from the ADAPT-PD trial in JAMA Neurology, showcasing the effectiveness of its BrainSense™ Adaptive deep brain stimulation (aDBS) for Parkinson’s disease. This pivotal trial, the largest of its kind, involved leading neurologists and neurosurgeons across 10 centers in the U.S., Canada, and Europe, marking a significant advancement in managing Parkinson’s disease through closed-loop neuromodulation technology.
Medtronic plc has announced the publication of results from the Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial in the Journal of the American Medical Association (JAMA) Neurology. The trial assessed the chronic use of the BrainSense™ Adaptive deep brain stimulation (aDBS) for individuals with Parkinson’s disease. This pivotal trial, the largest and longest of its kind, evaluated the effectiveness of closed-loop neuromodulation. Conducted globally, it involved leading neurologists and neurosurgeons across 10 centers in the United States, Canada, and Europe. The study marks a significant advancement in managing Parkinson’s disease, leveraging BrainSense™ technology to develop an adaptive DBS system that detects and classifies different brain signals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
